Evidence map›Paper›PMID 40838866›Full record

ArticleTransplantation2025

MHC Class II Sharing Appears to Promote Intestinal Allograft Tolerance Through Linked Suppression in a Large Animal Model.

M Esad Gunes, Satyajit Patwardhan, Sarah Merl, Kryscilla Yang, Rebecca Jones, Bryan Chen, Elin Manell, Julie Hong, Philip Jordache, Hussein Atta and 18 more

Abstract read
In one paragraph

Article in Transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

M Esad GunesColumbia Center of Translational Immunology, Columbia University, New York, NY.
Satyajit PatwardhanColumbia Center of Translational Immunology, Columbia University, New York, NY.
Sarah MerlColumbia Center of Translational Immunology, Columbia University, New York, NY.
Kryscilla YangColumbia Center of Translational Immunology, Columbia University, New York, NY.
Rebecca JonesColumbia Center of Translational Immunology, Columbia University, New York, NY.
Bryan ChenColumbia Center of Translational Immunology, Columbia University, New York, NY.
Elin ManellColumbia Center of Translational Immunology, Columbia University, New York, NY.
Julie HongColumbia Center of Translational Immunology, Columbia University, New York, NY.
Philip JordacheColumbia Center of Translational Immunology, Columbia University, New York, NY.
Hussein AttaColumbia Center of Translational Immunology, Columbia University, New York, NY.
Ishit ChauhanColumbia Center of Translational Immunology, Columbia University, New York, NY.
Ahmed AlmesallmyColumbia Center of Translational Immunology, Columbia University, New York, NY.
Abrar ShamimColumbia Center of Translational Immunology, Columbia University, New York, NY.
Obinna AgwunchaColumbia Center of Translational Immunology, Columbia University, New York, NY.
Harko MulderColumbia Center of Translational Immunology, Columbia University, New York, NY.
Amarnath DasariColumbia Center of Translational Immunology, Columbia University, New York, NY.
Dominik HajosiColumbia Center of Translational Immunology, Columbia University, New York, NY.
Robert J HawleyColumbia Center of Translational Immunology, Columbia University, New York, NY.
Greg NowakColumbia Center of Translational Immunology, Columbia University, New York, NY.
Marcus PereiraColumbia Center of Translational Immunology, Columbia University, New York, NY.
Huaibin Mabel KoColumbia Center of Translational Immunology, Columbia University, New York, NY.
Dilrukshi Ekanayake-AlperColumbia Center of Translational Immunology, Columbia University, New York, NY.
Mercedes MartinezColumbia Center of Translational Immunology, Columbia University, New York, NY.
David H SachsColumbia Center of Translational Immunology, Columbia University, New York, NY.
Tomoaki KatoColumbia Center of Translational Immunology, Columbia University, New York, NY.
Kazuhiko YamadaColumbia Center of Translational Immunology, Columbia University, New York, NY.
Megan SykesColumbia Center of Translational Immunology, Columbia University, New York, NY.
Joshua WeinerColumbia Center of Translational Immunology, Columbia University, New York, NY.

Funding

Intestinal allograft tolerance in large animalsR01AI138547 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SYKES, MEGAN, YAMADA, KAZUHIKO · 2018 to 2022
$3.9M
Defining the relationship between host-microbiome interactions and rejection after intestinal transplantationK23AI156026 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WEINER, JOSHUA · 2021 to 2025
$962k
Five-laser Aurora spectral flow cytometerS10OD030282 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CREUSOT, REMI J · 2022 to 2022
$361k
NIAID NIH HHS K23 AI156026NIAID NIH HHS R01 AI138547NIH HHS S10 OD030282
6 · The paper itself

Abstract

backgroundThe relative importance of major histocompatibility complex (MHC) class I and class II matching for the induction of transplantation tolerance remains unclear. We studied selective mismatches in a clinically relevant model of intestinal transplantation (ITx) in swine with defined MHC genotypes.

methodsWe performed orthotopic ITx between MHC haplotype-matched (n = 6), partially matched (having class II alleles with marked overlap, n = 2), and fully mismatched (n = 4) pairs. Immunosuppression mirrored our clinical protocol and was weaned off between days 90 and 140.

resultsThe fully mismatched animals did not develop evidence of tolerance. In contrast, the partially matched animals developed a previously undefined form of "split tolerance" characterized by local graft tolerance mediated by donor regulatory T cells (Treg). In haplotype-matched animals, which share 1 full class II allele, Treg were also detectable in the periphery, where they appeared to promote donor-specific hyporesponsiveness and durable mixed chimerism. In vitro analyses, including a novel mucosal mixed lymphocyte reaction assay, suggested that the mechanism by which class II sharing promotes Treg-mediated tolerance is via linked suppression to allele combinations coexpressed on the same antigen-presenting cell in vivo.

conclusionsBecause humans often share some class II antigenic specificities that can be determined by tissue typing pretransplant, these findings may have important implications for the induction of clinical tolerance to ITx.

Indexed as

Graft SurvivalHistocompatibility Antigens Class IIIntestinesTransplantation ToleranceAllograftsAnimalsGraft RejectionHaplotypesHistocompatibility TestingLymphocyte Culture Test, MixedModels, AnimalOrgan TransplantationSus scrofaSwineT-Lymphocytes, RegulatoryTransplantation ChimeraHistocompatibility Antigens Class II

Identifiers

PMID40838866
PMCPMC12353661

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.